apl. Prof. Dr. Bernd Spriewald

Medizinische Fakultät

Outcome of 841 Older Patients (> 55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols (2022) Goekbuget N, Viardot A, Steffen B, Hahn J, Spriewald B, Martin S, Raffel S, et al. Conference contribution Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) (2022) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution Primary cutaneous manifestation of systemically aggressive diffuse large B-cell lymphoma (2022) Bender-Säbelkampf S, Spriewald B, Berking C, Erdmann M, Wagner N Conference contribution Correlation of Anti-HLA IgA Alloantibodies and Fc Receptor Motives with Kidney Allograft Survival (2022) Arnold M, Steffen U, Wiesener M, Bach C, Spriewald B, Lindemann M Journal article Correlation of Fc Receptor Polymorphisms with Pneumococcal Antibodies in Vaccinated Kidney Transplant Recipients (2022) Arnold M, Heinemann FM, Oesterreich S, Wilde B, Gackler A, Goldblatt D, Spriewald B, et al. Journal article Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute BLymphoblastic Leukemia (INITIAL-1 trial) (2021) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution Increased Levels of sCD30 Have No Impact on the Incidence of Early ABMR and Long-Term Outcome in Intermediate-Risk Renal Transplant Patients With Preformed DSA (2021) Drasch T, Bach C, Luber M, Spriewald B, Utpatel K, Büttner-Herold M, Banas B, Zecher D Journal article β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression (2021) Hofbauer D, Mougiakakos D, Broggini L, Zaiss M, Büttner-Herold M, Bach C, Spriewald B, et al. Journal article SARS-CoV-2-seronegative subjects target CTL epitopes in the SARS-CoV-2 nucleoprotein cross-reactive to common cold coronaviruses (2021) Schmidt K, Nganou-Makamdop K, Tenbusch M, El Kenz B, Maier C, Lapuente D, Überla K, et al. Conference contribution SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses (2021) Schmidt K, Nganou-Makamdop K, Tenbusch M, El Kenz B, Maier C, Lapuente D, Überla K, et al. Journal article